Inclusion Criteria:  18-65 years old AR patients (according to ARIA guidelines) Mono-sensitized to HDM and had AR symptoms after HDM exposure; Participants had at least 2 nasal symptoms(sneezing, runny nose, itching, nasal congestion) in the screening period ARCT score ≥20 after 2-week INS combined with AH1 treatment at run-in period had adequent informed and given their consent to participate in the study.  Exclusion Criteria:  Pregnant or lactating women, patients with malignant tumor, patients with congenital or acquired immunodeficiency disease, patients with mental illness Acute upper respiratory infection in the run-in period History of chronic sinusitis with nasal polyps Severe deviation of nasal septum received allergen immunotherapy in the past 5 years received biological therapy in the past 6 months Acute upper respiratory tract infection in run-in period Patients who failed to achieve AR control in the run-in period Patients who are participating in other clinical trials patients who are not suitable for this clinical trial due to other reasons (evaluated by investigators).